Nuheara ( ) - 株価, ニュースと分析ASX:NUH

NUH 株式概要

A wearables technology company, engages in the development and commercialization of hearing technology and products as regulated medical devices in Australia, the United States, and internationally.

会社概要

NUH ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	3/6
配当金	0/6

報酬

リスク分析

過去5年間で収益は年間11.8%減少しました。

過去1年間で株主の希薄化は大幅に進んだ

株式の流動性は非常に低い

意味のある収益がありません ( A$2M )

+2 さらなるリスク

Nuheara Limited 競合他社

BirdDog Technology

ASX:BDT

AU$10.5m

Zimi

ASX:ZMM

AU$4.9m

ASX:TZL

AU$19.2m

Ambertech

ASX:AMO

AU$15.7m

価格と性能

の歴代最高値、変動、値下がりまとめNuheara
過去の株価
現在の株価	AU$0.081
52週高値	AU$0.21
52週安値	AU$0.07
ベータ	1.87
11ヶ月の変化	0%
3ヶ月変化	3.85%
1年変化	-42.14%
33年間の変化	-90.36%
5年間の変化	-94.53%
IPOからの変化	-91.38%

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Oct 09

Recent updates

株主還元

	NUH	AU Tech	AU 市場
7D	0%	-2.5%	0.2%
1Y	-42.1%	19.2%	16.6%

業界別リターン: NUH過去 1 年間で19.2 % の収益を上げたAustralian Tech業界を下回りました。

リターン対市場: NUHは、過去 1 年間で16.6 % のリターンを上げたAustralian市場を下回りました。

価格変動

Is NUH's price volatile compared to industry and market?
NUH volatility
NUH Average Weekly Movement	n/a
Tech Industry Average Movement	6.4%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.5%

安定した株価: NUH過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間のNUHのボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	n/a	Justin Miller	www.nuheara.com

Nuheara Limited 基礎のまとめ

Nuheara の収益と売上を時価総額と比較するとどうか。
NUH 基礎統計学
時価総額	AU$21.76m
収益（TTM）	-AU$12.62m
売上高(TTM)	AU$1.93m

11.3x

P/Sレシオ

-1.7x

PER（株価収益率

NUH は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
NUH 損益計算書（TTM）
収益	AU$1.93m
売上原価	AU$2.88m
売上総利益	-AU$951.47k
その他の費用	AU$11.67m
収益	-AU$12.62m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.047
グロス・マージン	-49.27%
純利益率	-653.33%
有利子負債／自己資本比率	46.3%

NUH の長期的なパフォーマンスは？

過去の実績と比較を見る

NUH 株式概要

報酬

リスク分析

Nuheara Limited 競合他社

ASX:BDT

AU$10.5m

ASX:ZMM

AU$4.9m

ASX:TZL

AU$19.2m

ASX:AMO

AU$15.7m

価格と性能

最新ニュース

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Recent updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal

New minor risk - Share price stability

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Insufficient new directors

Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.025401 million.

Nuheara Limited Receives US FDA Approval and Launches HP Hearing PRO

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Nuheara Limited Announces the Resignation of Jean-Marie Rudd as CFO

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Nuheara Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited Welcomes US Food and Drug Administration's Final Ruling, Establishing A Regulatory Category for Over-The-Counter (Otc) Hearing Aids in the United States

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Limited Announces Executive Changes

Nuheara Limited has filed an IPO in the amount of AUD 5 million.

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Submits 510(k) for U.S. FDA Clearance

Nuheara Announces Executive Changes

Nuheara Limited Announces Successful Clinical Trial Self-Fitted Hearing Aids

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Nuheara Clinical Trial and FDA 510(K) Pathway Update

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Nuheara Limited Provides Update on Clinical Trial and Pathway to FDA 510(K) Approval

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020)

Nuheara Limited Receives U.S. FDA Registration and Hearing Aid Device Listing

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020)

What Can We Make Of Nuheara's (ASX:NUH) CEO Compensation?

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 11.5 million.

Nuheara Limited announced that it expects to receive AUD 11.5 million in funding

Nuheara Limited Appoints Warwick Sauer as Director

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Nuheara Receives $2 Million Phase II Works with HP Inc

Full year earnings released - AU$0.011 loss per share

Nuheara Limited announced that it has received funding

株主還元

価格変動

会社概要

Nuheara Limited 基礎のまとめ

11.3x

-1.7x

収益と収入